Strategies for the prevention of hip fracture.

Hip fractures are associated with 10% to 20% excess mortality in the first year and cause functional disability in most survivors. An estimated 17% of white women in the United States will sustain a hip fracture after the age of 50 years. Despite the availability of evidence-based guidelines for hip fracture prevention, routine screening and preventive measures have not been incorporated into standard primary care practice. Many physicians lack adequate knowledge to initiate bone mineral density testing and treatment with preventive medications to decrease the incidence of osteoporosis and fractures. Furthermore, patients are less likely to request information about bone health than about diseases for which systematic screening and prevention protocols have been established. This review describes preventive measures to decrease hip fracture in postmenopausal women, including screening by bone mineral density testing, risk factor assessment, and chemoprevention. Existing guidelines are summarized, and dilemmas regarding their implementation are discussed.

[1]  G E Dallal,et al.  Effect of calcium and vitamin D supplementation on bone density in men and women 65 years of age or older. , 1997, The New England journal of medicine.

[2]  S. Cummings,et al.  Bone density at various sites for prediction of hip fractures , 1993, The Lancet.

[3]  O. Johnell,et al.  Risk of Hip Fracture Derived from Relative Risks: An Analysis Applied to the Population of Sweden , 2000, Osteoporosis International.

[4]  S. Cummings,et al.  The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation. , 1999, JAMA.

[5]  J. Cauley,et al.  Broadband ultrasound attenuation predicts fractures strongly and independently of densitometry in older women. A prospective study. Study of Osteoporotic Fractures Research Group. , 1997, Archives of Internal Medicine.

[6]  M. Morris,et al.  Clinical Reporting to Primary Care Physicians Leads to Increased Use and Understanding of Bone Densitometry and Affects the Management of Osteoporosis , 1998, Annals of Internal Medicine.

[7]  T. Harris,et al.  Prevalence of low femoral bone density in older U.S. women from NHANES III , 1995, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[8]  S. Cummings,et al.  Risk factors for hip fracture in white women. Study of Osteoporotic Fractures Research Group. , 1995, The New England journal of medicine.

[9]  B. Dawson-Hughes,et al.  Calcium Supplement and Bone Medication Use in a US Medicare Health Maintenance Organization , 2002, Osteoporosis International.

[10]  O. Geling,et al.  Missed opportunities for prevention of osteoporotic fracture. , 2002, Archives of internal medicine.

[11]  D. Kiel,et al.  A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the prevent recurrence of osteoporotic fractures study. PROOF Study Group. , 2000, The American journal of medicine.

[12]  Orthopaedic Surgeons Panel On Falls Prevention Guideline for the Prevention of Falls in Older Persons , 2001 .

[13]  C C Glüer,et al.  Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. , 1999, JAMA.

[14]  M. Hochberg,et al.  Recommendations for the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis , 1996 .

[15]  A. Berg Postmenopausal hormone replacement therapy for the primary prevention of chronic conditions , 2003 .

[16]  David W. Bates,et al.  CLINICAL USE OF BONE DENSITOMETRY , 1991 .

[17]  J. Kaufman,et al.  Interest of a Prescreening Questionnaire to Reduce the Cost of Bone Densitometry , 2002, Osteoporosis International.

[18]  P. Dargent-Molina,et al.  Use of Clinical Risk Factors in Elderly Women with Low Bone Mineral Density to Identify Women at Higher Risk of Hip Fracture: The EPIDOS Prospective Study , 2002, Osteoporosis International.

[19]  Mahmood Puzirandeh Does patient partnership in continuing medical education (CME) improve the outcome in osteoporosis management? , 2002 .

[20]  François Duboeuf,et al.  Vitamin D3 and Calcium to Prevent Hip Fractures in Elderly Women , 1993 .

[21]  B. Ettinger,et al.  Management of postmenopausal osteoporosis: position statement of the North American Menopause Society. , 2002, Menopause.

[22]  L. Gillespie,et al.  Hip protectors for preventing hip fractures in the elderly. , 2001, The Cochrane database of systematic reviews.

[23]  G. Guyatt,et al.  IV. Meta-Analysis of Raloxifene for the Prevention and Treatment of Postmenopausal Osteoporosis , 2002 .

[24]  E. Barrett-Connor,et al.  Identification and fracture outcomes of undiagnosed low bone mineral density in postmenopausal women: results from the National Osteoporosis Risk Assessment. , 2001, JAMA.

[25]  Harry K. Genant,et al.  Reduction of Vertebral Fracture Risk in Postmenopausal Women With Osteoporosis Treated With Raloxifene: Results From a 3-year Randomized Clinical Trial , 2000 .

[26]  K. Fink,et al.  Screening for osteoporosis in postmenopausal women. , 2004, American family physician.

[27]  E. Barrett-Connor,et al.  Raloxifene and Cardiovascular Events in Osteoporotic Postmenopausal Women: Four-Year Results From the MORE (Multiple Outcomes of Raloxifene Evaluation) Randomized Trial , 2002 .

[28]  J. Peipert,et al.  Screening for Osteoporosis in Postmenopausal Women: Recommendations and Rationale , 2002, Annals of Internal Medicine.

[29]  J. Reginster,et al.  Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. , 2001, The New England journal of medicine.

[30]  Deborah Grady,et al.  Cardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study follow-up (HERS II). , 2002, JAMA.

[31]  R. Parker,et al.  Combination therapy with hormone replacement and alendronate for prevention of bone loss in elderly women: a randomized controlled trial. , 2003, JAMA.

[32]  Lex M Bouter,et al.  Prevention of hip fractures by external hip protectors: a randomized controlled trial. , 2003, JAMA.

[33]  V. Kaklamani,et al.  Assessment of physician responses to abnormal results of bone densitometry studies. , 2000, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists.

[34]  Lillemor Lundin-Olsson,et al.  Fall and Injury Prevention in Older People Living in Residential Care Facilities: A Cluster Randomized Trial , 2002, Annals of Internal Medicine.

[35]  B. Kvern,et al.  Evaluation of a problem‐based learning workshop using pre‐ and post‐test objective structured clinical examinations and standardized patients , 2000, The Journal of continuing education in the health professions.

[36]  O. Johnell,et al.  Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures , 1996 .

[37]  S. Cummings,et al.  The Effect of Raloxifene on Risk of Breast Cancer in Postmenopausal Women: Results From the MORE Randomized Trial , 2000 .

[38]  Gordon Guyatt,et al.  Meta-analyses of therapies for postmenopausal osteoporosis. IX: Summary of meta-analyses of therapies for postmenopausal osteoporosis. , 2002, Endocrine reviews.

[39]  A. Warnke,et al.  controlled trial protectors in nursing homes: cluster randomised Effect on hip fractures of increased use of hip , 2004 .

[40]  E. Barrett-Connor,et al.  Raloxifene and cardiovascular events in osteoporotic postmenopausal women: four-year results from the MORE (Multiple Outcomes of Raloxifene Evaluation) randomized trial. , 2002, JAMA.

[41]  G. Guyatt,et al.  Meta-analyses of therapies for postmenopausal osteoporosis. IV. Meta-analysis of raloxifene for the prevention and treatment of postmenopausal osteoporosis. , 2002, Endocrine reviews.

[42]  E. Vittinghoff,et al.  Noncardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study follow-up (HERS II). , 2002, JAMA.

[43]  S. Cummings,et al.  Clinical use of bone densitometry: scientific review. , 2002, JAMA.

[44]  J. Reginster,et al.  Strontium ranelate reduces the risk of hip fracture in women with postmenopausal osteoporosis , 2002 .

[45]  B. Ettinger,et al.  Clinic visits and hospital admissions for care of acid-related upper gastrointestinal disorders in women using alendronate for osteoporosis. , 1998, The American journal of managed care.

[46]  Gabriele Meyer,et al.  Effect on hip fractures of increased use of hip protectors in nursing homes: cluster randomised controlled trial , 2003, BMJ : British Medical Journal.

[47]  Stephen B. Hulley,et al.  Noncardiovascular disease outcomes during 6.8 years of hormone therapy : Heart and Estrogen/Progestin Study fellow-up (HERS II) , 2002 .

[48]  L. Bouter,et al.  Ultrasound Measurements for the Prediction of Osteoporotic Fractures in Elderly People , 1999, Osteoporosis International.

[49]  Susan Mehle,et al.  Barriers to osteoporosis identification and treatment among primary care physicians and orthopedic surgeons. , 2002, Mayo Clinic proceedings.

[50]  I. Zuckerman,et al.  Patterns of pharmacotherapy and counseling for osteoporosis management in visits to US ambulatory care physicians by women. , 2002, Archives of internal medicine.

[51]  B. Stuckey,et al.  Alendronate prevents loss of bone density associated with discontinuation of hormone replacement therapy: a randomized controlled trial. , 2003, Archives of internal medicine.

[52]  Y. Carter,et al.  Education and debate , 2022 .

[53]  P. Geusens,et al.  Performance of risk indices for identifying low bone density in postmenopausal women. , 2002, Mayo Clinic proceedings.

[54]  M S Calvo,et al.  Prevalence of Low Femoral Bone Density in Older U.S. Adults from NHANES III , 1997, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[55]  Stella M. Yu Healthy People 2010 , 1998, Maternal and Child Health Journal.

[56]  L. Melton,et al.  Medical Expenditures for the Treatment of Osteoporotic Fractures in the United States in 1995: Report from the National Osteoporosis Foundation , 1997, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[57]  Charles Kooperberg,et al.  Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. , 2002, JAMA.

[58]  Susan R. Johnson,et al.  Osteoporosis prevention, diagnosis, and therapy. , 2001, JAMA.

[59]  J. Vahle,et al.  Skeletal Changes in Rats Given Daily Subcutaneous Injections of Recombinant Human Parathyroid Hormone (1-34) for 2 Years and Relevance to Human Safety , 2002, Toxicologic pathology.

[60]  Michael C. Nevitt,et al.  Fracture Risk Reduction With Alendronate in Women With Osteoporosis: The Fracture Intervention Trial , 2001 .

[61]  S. Cummings,et al.  Epidemiology and outcomes of osteoporotic fractures , 2002, The Lancet.

[62]  Uspstf Postmenopausal hormone replacement therapy for the primary prevention of chronic condition. Recommendations and rationale. U.S. Preventive Services Task Force. , 2003, American family physician.

[63]  Dami,et al.  EFFECT OF RISEDRONATE ON THE RISK OF HIP FRACTURE IN ELDERLY WOMEN EFFECT OF RISEDRONATE ON THE RISK OF HIP FRACTURE IN ELDERLY WOMEN , 2001 .

[64]  M. Hochberg,et al.  Recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis: 2001 Update: American College of Rheumatology Ad Hoc Committee on glucocorticoid-induced osteoporosis , 2001 .

[65]  R. Doll,et al.  Effect of four monthly oral vitamin D3 (cholecalciferol) supplementation on fractures and mortality in men and women living in the community: randomised double blind controlled trial , 2003, BMJ : British Medical Journal.